VRNA
Price
$106.38
Change
+$0.13 (+0.12%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
9.19B
48 days until earnings call
ZYME
Price
$16.30
Change
-$0.06 (-0.37%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
1.24B
Interact to see
Advertisement

VRNA vs ZYME

Header iconVRNA vs ZYME Comparison
Open Charts VRNA vs ZYMEBanner chart's image
Verona Pharma
Price$106.38
Change+$0.13 (+0.12%)
Volume$4.71K
Capitalization9.19B
Zymeworks
Price$16.30
Change-$0.06 (-0.37%)
Volume$7.57K
Capitalization1.24B
VRNA vs ZYME Comparison Chart in %
Loading...
VRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
VRNA vs. ZYME commentary
Sep 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is VRNA is a Hold and ZYME is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 25, 2025
Stock price -- (VRNA: $106.25 vs. ZYME: $16.36)
Brand notoriety: VRNA and ZYME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: VRNA: 76% vs. ZYME: 126%
Market capitalization -- VRNA: $9.19B vs. ZYME: $1.24B
VRNA [@Biotechnology] is valued at $9.19B. ZYME’s [@Biotechnology] market capitalization is $1.24B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

VRNA’s FA Score shows that 1 FA rating(s) are green whileZYME’s FA Score has 0 green FA rating(s).

  • VRNA’s FA Score: 1 green, 4 red.
  • ZYME’s FA Score: 0 green, 5 red.
According to our system of comparison, ZYME is a better buy in the long-term than VRNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

VRNA’s TA Score shows that 3 TA indicator(s) are bullish while ZYME’s TA Score has 6 bullish TA indicator(s).

  • VRNA’s TA Score: 3 bullish, 4 bearish.
  • ZYME’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, ZYME is a better buy in the short-term than VRNA.

Price Growth

VRNA (@Biotechnology) experienced а -0.02% price change this week, while ZYME (@Biotechnology) price change was +3.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was +10.70%, and the average quarterly price growth was +54.52%.

Reported Earning Dates

VRNA is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRNA($9.19B) has a higher market cap than ZYME($1.24B). VRNA YTD gains are higher at: 128.790 vs. ZYME (11.749). VRNA has higher annual earnings (EBITDA): -34.62M vs. ZYME (-69.77M). VRNA has more cash in the bank: 438M vs. ZYME (281M). ZYME has less debt than VRNA: ZYME (18.7M) vs VRNA (244M). VRNA has higher revenues than ZYME: VRNA (222M) vs ZYME (123M).
VRNAZYMEVRNA / ZYME
Capitalization9.19B1.24B742%
EBITDA-34.62M-69.77M50%
Gain YTD128.79011.7491,096%
P/E RatioN/AN/A-
Revenue222M123M180%
Total Cash438M281M156%
Total Debt244M18.7M1,305%
FUNDAMENTALS RATINGS
VRNA vs ZYME: Fundamental Ratings
VRNA
ZYME
OUTLOOK RATING
1..100
8572
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
43
Fair valued
PROFIT vs RISK RATING
1..100
2100
SMR RATING
1..100
9795
PRICE GROWTH RATING
1..100
3742
P/E GROWTH RATING
1..100
10059
SEASONALITY SCORE
1..100
8545

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ZYME's Valuation (43) in the Pharmaceuticals Major industry is somewhat better than the same rating for VRNA (81) in the Pharmaceuticals Other industry. This means that ZYME’s stock grew somewhat faster than VRNA’s over the last 12 months.

VRNA's Profit vs Risk Rating (2) in the Pharmaceuticals Other industry is significantly better than the same rating for ZYME (100) in the Pharmaceuticals Major industry. This means that VRNA’s stock grew significantly faster than ZYME’s over the last 12 months.

ZYME's SMR Rating (95) in the Pharmaceuticals Major industry is in the same range as VRNA (97) in the Pharmaceuticals Other industry. This means that ZYME’s stock grew similarly to VRNA’s over the last 12 months.

VRNA's Price Growth Rating (37) in the Pharmaceuticals Other industry is in the same range as ZYME (42) in the Pharmaceuticals Major industry. This means that VRNA’s stock grew similarly to ZYME’s over the last 12 months.

ZYME's P/E Growth Rating (59) in the Pharmaceuticals Major industry is somewhat better than the same rating for VRNA (100) in the Pharmaceuticals Other industry. This means that ZYME’s stock grew somewhat faster than VRNA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
VRNAZYME
RSI
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
74%
Bullish Trend 2 days ago
76%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
71%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 13 days ago
79%
Bullish Trend 7 days ago
82%
Declines
ODDS (%)
Bearish Trend 6 days ago
81%
Bearish Trend 23 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
80%
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
VRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BIS13.670.16
+1.21%
ProShares UltraShort Nasdaq Biotech
SABA9.170.04
+0.44%
Saba Capital Income & Opportunities Fund II
EZET31.530.13
+0.41%
Franklin Ethereum ETF
VTC78.490.13
+0.17%
Vanguard Total Corporate Bond ETF
ATFV35.45-0.33
-0.92%
Alger 35 ETF

VRNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRNA has been loosely correlated with RYTM. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if VRNA jumps, then RYTM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRNA
1D Price
Change %
VRNA100%
N/A
RYTM - VRNA
47%
Loosely correlated
-0.30%
IRON - VRNA
42%
Loosely correlated
+1.08%
ZYME - VRNA
42%
Loosely correlated
-1.03%
BBIO - VRNA
39%
Loosely correlated
-0.08%
OCUL - VRNA
36%
Loosely correlated
+0.41%
More

ZYME and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZYME has been loosely correlated with NRIX. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ZYME jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZYME
1D Price
Change %
ZYME100%
-1.03%
NRIX - ZYME
50%
Loosely correlated
-2.25%
VRDN - ZYME
48%
Loosely correlated
+0.05%
XNCR - ZYME
48%
Loosely correlated
-0.67%
BEAM - ZYME
48%
Loosely correlated
-2.79%
RVMD - ZYME
47%
Loosely correlated
-0.46%
More